This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Aplaviroc

GlaxoSmithKline plc

Drug Names(s): GW873140, ONO-4128

Description: GW-873140 is a novel cellular chemokine receptor (CCR5) antagonist that binds specifically to human CCR5. The CCR5 receptor is believed to be the predominant co-receptor used by HIV to enter and infect vital immune cells, called CD4 cells. Blocking the CCR5 receptor with an antagonist may provide an alternative mechanism for inhibiting HIV infection of CD4 cells.

Deal Structure: GW-873140 (ONO-4128) was licensed by Ono Pharmaceuticals to GSK for worldwide commercialization.


Aplaviroc News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug